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Abstract
Globally, leptospirosis poses an increasing public health problem, as evidenced by markedly increasing incidence rates and multiple out-
breaks in all continents. Yet, the disease is severely neglected and hence, its global burden is largely unknown. The estimated incidence
of about half a million severe human cases annually is probably an underestimation while the burden for animal health is unknown. It is
anticipated that current international initiatives will assess the global burden of leptospirosis, while mathematical modelling of transmis-
sion dynamics will allow the identiﬁcation and testing of appropriate intervention and outbreak response measures within the coming
years.
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Leptospirosis is an Existing and Growing
Public and Veterinary Health Problem
Leptospirosis is probably the most widespread and prevalent
zoonotic disease in the world [1]. Leptospirosis is difﬁcult
to diagnose both in the clinic and the laboratory. Therefore,
the disease is frequently not recognized and consequently
severely neglected. Leptospirosis is (re-)emerging globally
and numerous outbreaks have occurred worldwide during
the past decade. The most recent examples are the epidem-
ics in Nicaragua in 2007 [2], in Sri Lanka in 2008 [3,4] and in
the Philippines in 2009 [5], each affecting several thousands
of people and causing hundreds of deaths. However, the true
spread and increase of leptospirosis remains unknown, as
the quality and availability of diagnostic tests, testing facilities
and surveillance systems are highly variable and frequently
absent.
Most mammalian species are natural carriers of pathogenic
leptospires [6–8]. These include feral, semi-domestic and farm
and pet animals as important infection sources. The risk of
acquiring leptospirosis is associated with contact with animals.
Therefore, leptospirosis is an important occupational disease,
especially affecting farmers, slaughterhouse workers, pet
traders, veterinarians, rodent catchers and sewer workers.
The main route of infection by these spirochetes is proba-
bly by transmission through indirect contact with leptospires
secreted into the environment. Pathogenic leptospires sur-
vive longer in a warm and humid environment. Hence, the
disease is particularly prevalent in wet tropical and subtropi-
cal regions [6–8].
Also of importance are increasing international travel and
activities in tropical countries, with the subsequent introduc-
tion of leptospirosis cases from outside the industrialized
world and the emergence of leptospirosis as a recreational
disease. Leptospirosis is also a veterinary problem. Apart
from farmers and slaughterhouse personnel acquiring lepto-
spirosis, this zoonosis has a direct impact on the trade of
animals or meat. The main economic impact, however, is
caused by reproductive failures in livestock [9]. Usually
animal leptospirosis is not routinely monitored. It is consid-
ered an endemic disease and surveillance is only carried out
routinely for those endemic diseases for which there are
control programmes. Therefore, surveillance is largely limited
ª2011 The Authors
Clinical Microbiology and Infection ª2011 European Society of Clinical Microbiology and Infectious Diseases
REVIEW 10.1111/j.1469-0691.2011.03474.x
to diagnostic investigations and the subsequent collation of
diagnostic data in some countries.
In summary, the relevance of leptospirosis is that it poses
an existing and growing public and veterinary health problem.
It is unlikely that leptospires (and leptospirosis) can be
eradicated, as their main reservoirs are rodents, with rats
notably forming major sources of highly virulent serovars.
Transmission, Epidemiology and Clinical
Symptoms
Transmission
Pathogenic leptospires live in the kidneys of their natural
hosts. In addition, the genital tracts of domestic animals act
as sites of persistence [10–12]. A wide range of mammalian
species are carriers. Humans are considered dead end hosts,
although a recent report has shown that people can maintain
leptospires in certain ecosystems [13]. Leptospires are
excreted in urine into the environment, where they can sur-
vive for several months, depending on favourable environ-
mental conditions. Infection of accidental hosts occurs via
direct contact with the carrier’s urine or indirectly through a
urine-contaminated environment. Leptospires may also be
excreted in the products of abortion in domestic animal spe-
cies [10]. Pathogenic leptospires enter via skin abrasions and
cuts, and through the mucous membranes of the eyes, nose
(inhalation of contaminated aerosols) and mouth (consump-
tion of contaminated beverage and predator chain transmis-
sion [14]) and genital tracts (domestic animals). Penetration
through water-weakened skin is controversial. Unlike natural
hosts, accidental hosts often develop disease [6–8].
Epidemiology
To date nearly 300 pathogenic Leptospira serovars have been
identiﬁed and many more will follow. In general, each ser-
ovar is adapted to a certain mammalian host; rodents, insec-
tivores, dogs, pigs and cattle comprise the best known ones.
Serovars can be adapted to several hosts, while one host
might carry several distinct serovars. In addition, serovars
continue to adapt to new hosts because the cycle is complex
and dynamic. Vaccination pressures may also alter the distri-
bution of serovars in a species. Distribution and infection
patterns may thus change both by adaptation of serovars to
other hosts, and by the introduction of new host animals
into an area. Also climatic (global warming, El Nin˜o) and eco-
logical changes (e.g. introduction of new crops, expanding
cities and deforestation) will affect the distribution of Lepto-
spira serovars and consequently the prevalence and clinical
features of human cases, while anthropogenic practices and
animal management systems are likely to determine expo-
sure and infection risks [6,8].
Clinical symptoms
The lack of awareness of leptospirosis is mainly due to
the wide variety of symptoms seen in infected persons,
the often subclinical nature of the disease in animals, and
technically demanding laboratory tests making the disease
difﬁcult to diagnose both in the clinic and the laboratory
[15–18].
The illness varies from mild to severe, potentially fatal
[6,7,16–18], depending on a number of known and unknown
factors, among which the causal serovar and the host’s
immune status might be important. Worldwide, case fatality
rates range from 3 to >50% [7,15,19]. Clinical manifestations
may comprise fever, myalgias, severe headache, chills, diar-
rhoea, nausea and vomiting, oliguria/anuria, jaundice, conjunc-
tival suffusion, aseptic meningitis, haemorrhages, joint pain,
skin rash, cough, cardiac arrhythmia, psychosis and/or delir-
ium. Early acute disease presents with non-speciﬁc symptoms
of fever, myalgia and headache lacking any diagnostic hall-
marks suggestive of leptospirosis [7,15–20].
Because of its protean manifestations, leptospirosis mimics
many other infectious diseases, namely inﬂuenza, hepatitis,
dengue, Hantavirus infections or other viral haemorrhagic
fevers, yellow fever, malaria, brucellosis, borreliosis, typhoid
fever or other enteric diseases, and pneumonia [6–8,20–22],
together with a range of abortifacient diseases in animals
(such as brucellosis, neospirosis bovine virus diarrhoea, infec-
tious bovine rhinotracheitis and porcine circa virus). There-
fore, it is often misdiagnosed as any of these other diseases,
which generally encounter more awareness [20,21]. This
contributes to the cycle: under-diagnosis – under-reporting –
lack of awareness and neglect.
Diagnostic Methods
Conﬁrmation of a clinically suspected leptospirosis case in
the laboratory also has many bottlenecks. Standard tests, such
as culturing and the microscopic agglutination test (MAT), are
tedious, laborious and require well-equipped laboratories
with experienced staff and, therefore, are restricted to a few
‘expert’ centres. Because MAT is the reference test in sero-
diagnosis, an international proﬁciency testing scheme has
been developed to standardize its performance level at a glo-
bal scale [23]. However, novel or adapted simpliﬁed diagnos-
tic tests for diagnosis in both humans and animals are badly
needed. Several rapid tests for human use are currently avail-
able (Table 1). Meaningful multicentre comparisons have not
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been carried out between these tests, using sera from ade-
quately deﬁned cases, to ascertain their relative merits as
diagnostic tools. Also, these tests are for screening purposes
only, and results must be conﬁrmed by standard tests. In
addition, they are applicable only at a later stage of disease
when effective treatment with antibiotics is likely to fail.
Moreover, Leptospira related to reproductive failure in ani-
mals is a chronic condition associated with declining antibody
titres or the absence of detectable antibody titres. There is
an urgent need for robust and easy to use diagnostics, partic-
ularly during acute infection among humans and domestic
animals. In addition, it must be remembered that human and
veterinary diagnostic requirements differ in some respects,
as follows. In human leptospirosis the ﬁrst requirement is to
get a diagnosis and genus speciﬁc tests are suitable, whereas
in animals the individual is less important than the population
from which it comes. Therefore, it is important to get an
early diagnosis of the infecting serovar as control measures
such as vaccination are serovar dependant. Improved diag-
nostics will contribute to an improved case detection and a
consequent increased awareness and control of leptospirosis
and, hence, be beneﬁcial for veterinary public health care
and (national) economies.
Treatment and Control
In the past, adequate treatment has been shown to markedly
increase the chances of surviving leptospirosis and reduce
the number of days of illness [24]. For example, introduction
of peritoneal dialysis in cases of renal failure has markedly
reduced fatality rates [7]. Early antibiotic treatment is gener-
ally thought to be beneﬁcial to the course of disease while
treatment later on might reduce recovery periods and mini-
mize sequelae [25]. However, treatment with penicillin, the
drug of choice, is sometimes problematic, with rapid clear-
ance of leptospires associated with the life-threatening Jarish-
Herxheimer reaction.
In severe cases, high doses of intravenous penicillin (four
times a day, 2 million units) are recommended. In less severe
TABLE 1. Common diagnostic tests for leptospirosis
Test Sensitivitya,b,c, Speciﬁcitya,b Costsd Advantages Disadvantagese Reference
Culture 5–50% 100% €20f Provides evidence.
Veterinary and human
applicability
Too slow and difﬁcult [6,7,16]
Dark-Field
Microscopy (DFM)
104
bacteria/ml
Low; confusion
with protein
ﬁbres
<€1 Quick and early diagnosis.
Veterinary and human
applicability
Unreliable, requires
conﬁrmation
[6,7,16]
Microscopic
Agglutination
Test (MAT)
90% >90% €160f,g Gold standard. Veterinary
and human applicability
Requires a panel of life
antigens, difﬁcult
(expertise), laborious
(3 h), serology. Problems
with seronegative carrier
animals
[6,7,16]
IgM-ELISAh 84% 99% €48f,g Cost effective, can be
done without ELISA
Reader
Laborious (4 h), serology
Limited veterinary use
[7,16]
IgM-ELISAi >90% 88–95% €9–16g,j Cost effective and
relatively rapid (1–2 h)
Serology [7,16]
IgG-ELISA for cattle ca.90% 95% €6j 1 h Misses early immune
response
[53]
DriDot test 82% 95% €5–7g,j Easy, quick (30 s), cost
effective
Serology, needs
conﬁrmation by MAT.
No veterinary use
[7,16]
Lateral ﬂow test 81% 96% €2–5g,j Easy, quick (10 min), ﬁnger
prick blood, cost
effective
Serology, needs
conﬁrmation by MAT
[7,16]
Real-time PCR 100% 93% €100f Early diagnosis. Veterinary
and human applicability
Few tests validated (ref
56, 57), sophisticated
expensive equipment,
expertise
[7,16,55,56]
aSeveral studies indicate different percentages.
bSensitivity and speciﬁcity largely depends on a number of factors; stage of illness, type and producer of test and panel of clinical materials used for testing [6,57].
cSensitivity of culture depends mainly on the route and transport time to the laboratory. MAT is the gold standard and should be 100%. However, when comparing with cul-
ture this gold standard appears not optimal. Sensitivities of other serological tests are compared with MAT.
dExcluding costs for equipment.
eSerology has the disadvantage that it detects antibodies 7–10 days after the onset of the disease. This is too late for antibiotic treatment, which should start within the ﬁrst
4 days.
fIncludes personnel costs for execution of test based on costs formally recognized by The health assurance authority in The Netherlands (year 2011).
gBased on performance of one test. Please notice that serological conﬁrmation requires testing of both acute and convalescence serum samples for seroconversion or signiﬁ-
cant titre rise.
hIn-house ELISA.
iCommercial ELISA.
jCosts may vary, amongst other factors, due to the subjection to different import taxes raised in distinct countries.
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cases, oral antibiotics such as amoxicillin, ampicillin, doxycy-
cline or erythromycin can be prescribed. Third-generation
cephalosporins and quinolone antibiotics also seem to be
effective [7]. A number of antibiotics, in particular dihydro-
streptomycin, have been shown to be useful in the elimina-
tion of leptospires from carrier animals [26].
Due to the complex and dynamic epidemiology, there are
no general rules in the prevention and control of leptospiro-
sis in humans. However, domestic animal control measures
are often much simpler because they may be addressed on a
population basis and there is the possibility to isolate that
population. Direct or indirect contact with the urine of
excreting animals is the basis of infection. Prevention and
control thus mainly focus on the reduction of the infection
source and the prevention of penetration of leptospires into
the accidental host. Leptospires cannot usually be eradicated
as rodents and insectivores form major natural reservoirs.
Hardjo infection is probably the only exception where this
serovar is maintained by cattle and sheep and there are no
known wildlife hosts.
It will be obvious that a rational design of prevention and
control measures is based on the identiﬁcation of the infec-
tion source(s) and that the dynamic epidemiology requires a
permanent surveillance system. By deﬁnition, prevention and
control measures are tailor-made.
Prevention of transmission can be achieved by wearing
protective clothes (e.g. gloves, safety glasses and boots), but
this is not always practical; it is, for example, not an option
to wear boots in a paddy ﬁeld. Intervention can also be
achieved by improving water and food storages but, proba-
bly, increasing awareness about the disease and the infection
risks in clinicians, the population (notably risk groups) and
public health decision makers is an effective approach for
reducing infection risks.
Control of rodents can only be achieved by a constant
and intensive management of populations (e.g. muskrat con-
trol in the Netherlands). The use of rodenticides is risky
(generation of a resistant population) and needs expertise in
the composition and applicability of such control agents [27].
Changing the environment in order to reduce attractive eco-
logical niches (cleaning up garbage and improving sanitation)
is only feasible and realistic for major urban areas in the
industrialized world.
Infection risk from and between domestic animals can be
reduced by herd control measures. These include treatment
of carriers and/or vaccination. Treatment of Hardjo infec-
tions in cattle herds is applied in the Netherlands [26]. The
Dutch Hardjo control programme consists of a regular sur-
veillance that is undertaken by testing bulk-milk with a Hard-
jo-speciﬁc ELISA. Infected cattle are then treated with
dihydrostreptomycin and Hardjo-free farms are certiﬁed.
Participation in the programme led to a virtual eradication of
‘dairy fever’ in the country. Outside the Netherlands, vacci-
nation is the most common approach. Nevertheless, it
should be noted that both curative and prophylactic mea-
sures do not prevent Leptospira transmission but will largely
reduce excretion of leptospires [9,28,29]. Both approaches
should be combined with herd management.
There are vaccines available for cattle, dogs and pigs.
These whole-leptospire-based vaccines consist of a limited
panel of local serovars and give a short-term serovar-speciﬁc
protection. There has been a movement away from cheap
multivalent vaccines that produced very limited protection
[30] to more expensive monovalent products, which has led
to the development of vaccines that can provide at least
12 months of microbiological protection in cattle [31,32].
Vaccines for use in other domestic animals are being sub-
jected to more critical evaluation of the protection provided
than was the case in the past.
The use of subunit vaccine candidates is increasingly being
advocated because of their anticipated stronger or long-term
immunity and availability of non-toxic, potent adjuvants [33].
This may well be the way forward for vaccines for use in
humans and companion animals, particularly where cross-ser-
ovar protection may be an important consideration. It may
not be the most appropriate route for vaccines for use in food
producing animals where costs are critical and where immu-
nity is only required to a very limited number of serovars in a
species. The major production cost for such vaccines is the
cost of the bovine albumin used in growing the organism and
its subsequent removal from the ﬁnal product. This has been
obviated in some vaccines by the use of protein-free culture
media. Many of the vaccines available in Europe, but also in
other continents, notably in Latin America, are manufactured
in the USA. These vaccines are not necessarily appropriate to
regional requirements as they are not based on cultural evi-
dence of what are the local major problems, although there is
a trend for companies to better focus on at least European
needs. Studies on cattle maintaining with serovar Hardjo, have
shown that cell-mediated immunity is important in protective
immunity in that species [32,34] but protective immunity in
other animal species is poorly understood.
Information on human vaccines is limited. These are avail-
able only in certain countries, such as China [35], Cuba
[36,37], France [38] and Russia [39]. As in animals, these
vaccines are largely serovar-speciﬁc and protect for a rela-
tively short period. Boosting at regular intervals is necessary
to maintain protective titres of antibodies [7,35]. These vac-
cines are also focused on the local situation and do not
cover the needs in other regions where other serovars are
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endemic. Like the animal vaccines, those for humans are
composed of crude antigens consisting of leptospires killed
by phenol or formaldehyde that give unwanted side effects
(Shi Manhua, personal communication).
Geographical Distribution
Leptospirosis has a worldwide distribution but it is particu-
larly endemic in tropical and subtropical regions. It should be
noted that only a few countries have a notiﬁcation system
for leptospirosis and mainly hospitalized cases are recog-
nized. While it is generally accepted that leptospirosis is re-
emerging globally, and that notably lung haemorrhagic forms
are increasing in number [19,21], the true spread and
increase of leptospirosis cases remain unknown.
Numbers of conﬁrmed cases and fatalities provided by
national reference centres are likely to represent a marked
underestimation. This is based on the following consider-
ations:
1 The vast majority of countries do not have a notiﬁcation
system or notiﬁcation is not mandatory [38].
2 In The Netherlands, reporting is mandatory and notiﬁca-
tion is effective. Yet, our estimation for The Netherlands
is that we miss at least 30% of the severe cases. An esti-
mated 3- to 10-fold under-reporting of severe cases has
been indicated by several national reference centres in
Europe (Hartskeerl, personal observation).
3 Incidences are based on severe leptospirosis cases only.
In 70 – 90% of such cases hospitalization is needed
(Table 2) and conﬁrmation is often limited to hospitalized
patients.
4 The number of mild leptospirosis cases is unknown but
might be many times that of the severe cases.
5 Late sequelae occur but are not well assessed [40,41]. A
preliminary estimate of a 10-year investigation in the
Netherlands indicated the following: about 27% of the
patients had long-term complaints (especially with tired-
ness, myalgias, joint/back pain, headache, tinnitus and psy-
chotic complaints); 11% of the patients had serious
complaints (deﬁned as complaints for more than 1 year
or requiring reference to a clinician); and 1.3% of the
patients remained permanently unﬁt for work.
6 Worldwide incidences are (i) 0.1–1 cases per 100 000
population per year in regions with a temperate climate,
(ii) >10 cases per 100 000 population in humid (sub)
tropical regions and >100 cases per 100 000 population
affected during outbreaks [7]. The average case fatality
rate is about 10%.
Identiﬁcation of Speciﬁc Factors Triggering
Changes in the Distribution of the Disease
Survival of pathogenic Leptospira serovars outside the host,
being a unique feature within spirochetes, contributes to the
maintenance of infection cycles in reservoirs and to an
increased infection risk for accidental hosts, including
humans. Survival outside the host largely depends on humid
and warm conditions. Global warming and increased rainfall
are thus predictors of an increasing leptospirosis incidence.
Additionally, environmental changes that lead to migration of
natural hosts and improved conditions for the survival of
pathogenic leptospires, as well as socio-economic and politi-
cal factors resulting in increased human exposure, might
inﬂuence the occurrence of leptospirosis. Indeed, from the
end of the 20th century, massive urban and rural outbreaks
of leptospirosis have been observed in virtually all continents
[2–4,15–18,42]. These outbreaks involving thousands of cases
and many hundreds of deaths frequently occur in slums
peripheral to large cities [21]. The increasing world popula-
tion and urbanization in the 21st century will favour such
events.
Tropical countries beneﬁt from an increasing popularity as
holiday destinations, often with activities with a high risk of
infection, such as rafting, jungle tracking and caving. Notably
TABLE 2. Days of illness and of
hospitalization due to leptospirosis
Days of acute
diseasea Days of hospitalization
Intensive
care (%) Reference/sourceMedian Spread
Hospitalized
cases (%) Median Spread
14 2–84 68.0 ND ND ND [18]
15 6–36 88.0 8 1–30 64.0 Unpublished data, The
Netherlands (n = 49)b
17 2–90 100 10 1–35 33.0 [54] (n = 119)b
ND, not determined.
aTotal number of days of illness before and during hospitalization.
bBetween brackets the number of cases involved in the evaluation.
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South East Asia and Latin America, where incidences are
high, are exceedingly popular for tourists. This leads to a
higher import of leptospirosis cases into the industrialized
world, often with exotic serovars. Factors triggering changes
in the distribution of leptospirosis are listed in Table 3.
Burden and Transmission Dynamics
Modelling
As a true neglected infectious disease, the global burden of
leptospirosis is unknown. Current estimates of 350 000 to
500 000 severe cases annually [2,18,43] are likely to repre-
sent an underestimation. The magnitude of mild cases is
completely unknown. Considering the high case fatality rates
reported for severe leptospirosis, one might hypothesize that
the global burden of leptospirosis is similar to that of, for
example, dengue fever. Moreover, leptospirosis also poses a
veterinary burden, which might be considerable. Probably,
leptospirosis would rank high in the list of neglected tropical
diseases [44]. A major drawback in the assessment of the
burden of leptospirosis is the scarcity of models and hence
the lack of understanding of its dynamic transmission [45].
Available models concern basic aspects of the spread of lep-
tospirosis in Thailand [46], the infection dynamics of rodents
in Tanzania [47] and responses to some environmental driv-
ers [48]. The worldwide effects of climate change are appar-
ent from the evidence of global destabilization of natural
systems [49]. The study of the impacts of climate on human
health is an emerging research area. Thus, predictive model-
ling for the impacts of climate change on health is limited,
ﬁrstly because most aspects of human systems are not read-
ily amenable to modelling and, secondly, because of insufﬁ-
cient long-term data series on health outcomes. Recently,
the WHO has initiated the assessment of the global burden
of human leptospirosis and for that purpose has established
a Leptospirosis Burden Epidemiology Reference Group
(LERG). To date this initiative has provided the design of
basic transmission and susceptibility-infection (SI) models
[50,51] and will pursue this work on mathematical modelling
towards both the estimation of the global burden of the dis-
ease and the rational formulation of effective control and
prevention measures. It is hoped that the Food and Agricul-
ture Organization (FAO) and Ofﬁce International des
Epizooties (OIE) will join the effort to include the veterinary
side of the burden in line with the one-world-one-health
concept [52]. Until adequate models are available, general
adaptation measures can be effective at avoiding/reducing the
impacts on health, such as: (i) primary actions taken to pre-
vent or reduce human exposure to leptospires, through
improved housing and availability of potable water and sanita-
tion drainage; (ii) speciﬁc prevention measures regarding
changes in health risk or health status through the introduc-
tion of environmental controls (e.g. rodenticides, traps and
food protection) in response to an increase in the abundance
of rodents and a higher risk of Leptospira transmission; (iii)
increased disaster response capacity, with improved diagnosis
and treatment of cases; (iv) use of genomic and proteomic
knowledge to understand leptospiral biology, with direct
application in improved curative and prophylactic measures,
especially for impoverished populations; (v) established
national and international databases and improved accessibil-
ity to monitored data from unusual environmental events;
(vi) improved disease surveillance to reduce the number of
undetected and/or unreported cases; and (vii) improved pub-
lic education programmes to avoid leptospiral infection.
Conclusion
Leptospirosis is a prototype neglected infectious disease with
an unknown but probably considerable impact on veterinary
and public health. Leptospirosis will undoubtedly remain a
signiﬁcant veterinary public health threat for the coming
years regardless of the extent of climate changes that are
anticipated to favour an increase in its global incidence.
Therefore, the use of mathematical modelling in the assess-
ment of the global burden and infection risks, as initiated by
the WHO, will be a valuable tool for the future design of
adequate intervention and control measures.
TABLE 3. Factors triggering changes in the distribution of
leptospirosis
Factors increasing
incidence
Factors reducing
incidence
Factors triggering
changes in
distribution
Increased rainfall Decreased rainfall
Local food availability
and increased
rodent-densities
Decreased food
availability and lower
rodent-densities
Global warming
Urbanization (socio-
economic deprived
areas)
Improved sanitation
Lacking legislation on
surveillance,
notiﬁcation and
control/prevention
Improved vaccination
and/or prophylaxis
Growing communities
without timely
expansion of legislation
(e.g. the growing EU)
Holidays in tropical
countries
Military expeditions Changes in agriculture
land use and
deforestation
Trade in animals and
products
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